Leerink Partners analyst Jim Kelly maintained a Hold rating on Anthem (ANTM – Research Report) today and set a price target of $430.00. The company’s shares closed last Wednesday at $424.05, close to its 52-week high of $425.44.
According to TipRanks.com, Kelly is a 1-star analyst with an average return of -2.4% and a 41.2% success rate. Kelly covers the Healthcare sector, focusing on stocks such as Enanta Pharmaceuticals, Atea Pharmaceuticals, and Aligos Therapeutics.
Anthem has an analyst consensus of Strong Buy, with a price target consensus of $460.07, representing a 15.0% upside. In a report released today, RBC Capital also maintained a Hold rating on the stock with a $452.00 price target.
Based on Anthem’s latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $33.85 billion and net profit of $1.79 billion. In comparison, last year the company earned revenue of $29.26 billion and had a net profit of $2.28 billion.
Based on the recent corporate insider activity of 51 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of ANTM in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Indiana-based Anthem, Inc. was formed in 2004 after the merger of WellPoint Health Networks Inc. and Anthem, Inc. The company is one of the leading health insurance names, and provides medical benefits through a range of integrated healthcare plans and related services, along with a wide range of specialty products such as life and disability insurance benefits, dental, vision, behavioral health benefit services, as well as long-term care insurance and flexible spending accounts.
Read More on ANTM: